⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12787593 | 1.00 | — | — | |
| SCHEMBL8543694 | 0.87 | AGTR2 (0.80) | — | |
| SCHEMBL905714 | 0.85 | AGTR2 (0.62) | — | |
| SCHEMBL9192476 | 0.85 | AGTR2 (0.61) | — | |
| Candesartan SCHEMBL29687505 | 0.85 | ABCB11 (1.00) | — | |
| Candesartan SCHEMBL40832 | 0.85 | ABCB11 (1.00) | — | |
| SCHEMBL9195963 | 0.84 | AGTR2 (0.61) | — | |
| SCHEMBL9194328 | 0.84 | AGTR2 (0.61) | — | |
| SCHEMBL9194310 | 0.84 | AGTR2 (0.61) | — | |
| Carboxylic Acid Metabolite SCHEMBL29699808 | 0.83 | AGTR1 (1.00) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3873904-B1 | TETRAHYDROPYRAN (THP)-SUBSTITUTED BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2024-07-10 | — | — | EP | claimed |
| US-20220340569-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | MYOKARDIA INC (US) | 2022-10-27 | — | — | US | claimed |
| EP-4054588-A1 | METHODS OF TREATMENT WITH MYOSIN MODULATOR | MyoKardia, Inc. (US) | 2022-09-14 | — | — | EP | claimed |
| CN-114945372-A | Methods of treatment with myosin modulators | 迈奥卡迪亚公司 | 2022-08-26 | — | — | CN | claimed |
| US-20220106314-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | MYOKARDIA INC (US) | 2022-04-07 | — | — | US | claimed |
| EP-4736855-A2 | TETRAHYDROPYRAN (THP)-SUBSTITUTED BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12616697-B2 | Methods of treatment with myosin modulator | MyoKardia, Inc. (US) | 2026-05-05 | — | — | US | disclosed |
| EP-4464321-B1 | TETRAHYDROPYRAN (THP)-SUBSTITUTED BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250339395-A1 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | NOVARTIS PHARMACEUTICALS CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250325531-A1 | TREATMENT OF SYSTOLIC DYSFUNCTION | MyoKardia, Inc. (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250282779-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | MYOKARDIA INC (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250241903-A1 | TREATMENT OF SYSTOLIC DYSFUNCTION | MYOKARDIA INC (US) | 2025-07-31 | — | — | US | disclosed |
| EP-4054588-A1 | METHODS OF TREATMENT WITH MYOSIN MODULATOR | MyoKardia, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| CN-114945372-A | Methods of treatment with myosin modulators | 迈奥卡迪亚公司 | 2022-08-26 | — | — | CN | disclosed |
| US-20220265629-A1 | TREATMENT OF SYSTOLIC DYSFUNCTION AND HEART FAILURE WITH REDUCED EJECTION FRACTION WITH THE COMPOUND (R)-4-(1-((3-(DIFLUOROMETHYL)-1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-1-FLUOROETHYL)-N-(ISOXAZOL-3-YL)PIPERIDINE-1-CARBOXAMIDE | MyoKardia, Inc. (US) | 2022-08-25 | — | — | US | disclosed |
| US-20220257551-A1 | AMORPHOUS SOLID FORM OF COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND SODIUM CATIONS | NOVARTIS PHARMACEUTICALS CORPORATION | 2022-08-18 | — | — | US | disclosed |
| CN-113200934-B | Compound containing benzomorpholone-biphenyl skeleton and preparation method and application thereof | 郑州大学 | 2022-05-31 | — | — | CN | disclosed |
| US-20220106314-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | MYOKARDIA INC (US) | 2022-04-07 | — | — | US | disclosed |
| CN-114173782-A | Treatment of cardiac contractile dysfunction and heart failure with reduced ejection fraction using the compound (R) -4- (1- ((3- (difluoromethyl) -1-methyl-1H-pyrazol-4-yl) sulfonyl) -1-fluoroethyl) -N- (isoxazol-3-yl) piperidine-1-carboxamide | 迈奥卡迪亚公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2022047004-A1 | METHODS OF TREATMENT WITH MYOSIN MODULATOR | MyoKardia, Inc. (US) | 2022-03-03 | — | — | WO | disclosed |